

NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included. Medicines included are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
 - how well the medicine works,
 - which patients might benefit from it,
 - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
 - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each health board advise the ADTC on their preferred medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
----------	-------------------------	-----------------	------------------

anastrozole	primary prevention of breast cancer in post-menopausal people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
NCMAG113			
axicabtagene ciloleucel	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
Yescarta®			
SMC2695			
birch bark extract	treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older	Routinely available in line with local or regional guidance	09/12/2024
Filsuvez®			
SMC2651			
bismuth, metronidazole, tetracycline	In combination with omeprazole, for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with active or a history of H. pylori associated ulcers.	Routinely available in line with local or regional guidance	09/12/2024
Pylera®			
SMC2701			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
durvalumab Imfinzi® SMC2677	In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known EGFR mutations or ALK rearrangements	Not routinely available as not recommended for use in NHSScotland	09/12/2024
elranatamab Elrexio® SMC2669	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
enzalutamide Xtandi® SMC2742	Monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.	Not routinely available as not recommended for use in NHSScotland	09/12/2024
etranacogene dezaparvovec Hemgenix® SMC2649	treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
faricimab	Treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)	Routinely available in line with local or regional guidance	09/12/2024
Vabysmo			
SMC 2685		09/12/2024	
ivosidenib	Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
Tibsovo®			
SMC2664			
lebrikizumab	Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	09/12/2024
Ebglyss®			
SMC2707			
levodopa, carbidopa, entacapone	Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results.	Not routinely available as not recommended for use in NHSScotland	09/12/2024
Lecigon®			
SMC2507			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
linzagolix Yselty® SMC2631	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
mavacamten Camzyos® SMC2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
nivolumab, relatlimab Opdualag® SMC2645	First-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.	Routinely available in line with local or regional guidance	09/12/2024
pegunigalsidase alfa Elfabrio® SMC2665	for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2660</p>	<p>in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025</p>	<p>09/12/2024</p>
<p>pembrolizumab</p> <p>Keytruda®</p> <p>SMC2688</p>	<p>In combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung carcinoma at high risk of recurrence in adults.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>09/12/2024</p>
<p>quizartinib</p> <p>Vanflyta®</p> <p>SMC2699</p>	<p>In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:</p>	<p>09/12/2024</p>
<p>raloxifene</p> <p>NCMAG114</p>	<p>Primary prevention of breast cancer in post-menopausal people at moderate or high risk who are not suitable for on-label alternatives.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025</p>	<p>09/12/2024</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p>Selinexor</p> <p>Nexpovio</p> <p>SMC 2674</p>	<p>In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025</p>	<p>09/12/2024</p>
<p>Selinexor</p> <p>Nexpovio</p> <p>SMC 2673</p>	<p>In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025</p>	<p>09/12/2024</p>
<p>Semaglutide</p> <p>Wegovy</p> <p>SMC2497</p>	<p>An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of</p> <ul style="list-style-type: none"> • ≥30kg/m² (obesity), or • ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity. 	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025</p>	<p>09/12/2024</p>
<p>somapacitan</p> <p>Sogroya®</p> <p>SMC2629</p>	<p>Replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).</p>	<p>Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:</p>	<p>09/12/2024</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tamoxifen NCMAG115	Primary prevention of breast cancer in people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
teclistamab Tecvayli® SMC2668	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
tenecteplase Metalyse® SMC2697	In adults for the thrombolytic treatment of acute ischaemic stroke within 4.5 hours from last known well and after exclusion of intracranial haemorrhage.	Routinely available in line with local or regional guidance	09/12/2024
tirzepatide Mounjaro® SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m ² (obesity) or ≥ 27 kg/m ² to < 30 kg/m ² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024

Medicine	Condition being treated	NHSGGC Decision	Date of decision
trametinib NCMAG118	Treatment of low grade serous ovarian cancer after at least one line of platinum-based chemotherapy	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
trifluridine, tipiracil Lonsurf® SMC2654	In combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Routinely available in line with local or regional guidance	09/12/2024
vibegron Obgemsa® SMC2696	Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 17/02/2025	09/12/2024
zanubrutinib Brukinsa® SMC2684	Monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:	09/12/2024